Superworth

Voyager Therapeutics profit margin VYGR

Gross, operating and net profit as a share of revenue over the last twelve months, from 2019.

Net margin, 12 months
n/m
not a meaningful number
Peer median
11.1%

Voyager Therapeutics' net margin works out at −313% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY2025n/an/a
FY2024−81.3%n/a
FY202352.9%48.8%
FY2022n/an/a
FY2021n/an/a
FY202021.5%16.0%
FY2019−41.8%−49.5%
FY2018n/an/a
FY2017n/an/a
FY2016n/an/a
FY2015n/an/a
FY2014n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY25n/an/an/a
Q3 FY25n/an/an/a
Q2 FY25n/an/an/a
Q1 FY25n/an/an/a
Q4 FY24−81.3%−134.2 ptsn/a
Q3 FY2415.8%n/a5.5%
Q2 FY246.3%n/a−4.6%
Q1 FY24−2.6%n/a−14.3%
Q4 FY2352.9%n/a48.8%
Q3 FY23n/an/an/a

Against its peers

Companies in Healthcare nearest Voyager Therapeutics' size, closest first, today.

CompanyProfit margin
VYGRVoyager Therapeuticsn/m
KEQUKewaunee Scientific3.0%
ICCCImmucell2.6%
LFVNLifevantage2.8%
SPROSpero Therapeutics15.7%
PDEXPro DEX17.6%
APTAlpha Pro Tech6.8%
PLXProtalix BioTherapeutics23.5%
NATRNatures Sunshine Products3.7%
ELMDElectromed15.3%
UTMDUtah Medical Products29.0%
Peer median11.1%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Voyager Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.